ESMO 2021: CheckMate 649 Update Confirms Benefits of Adding Nivolumab to Chemotherapy for First-Line Treatment of Advanced Gastric/Esophageal Cancer
The addition of ipilimumab did not offer additional benefits but did increase toxicity
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.